U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8N4O2.H2O
Molecular Weight 198.1793
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THEOPHYLLINE

SMILES

O.CN1C2=C(N=CN2)C(=O)N(C)C1=O

InChI

InChIKey=INQSMEFCAIHTJG-UHFFFAOYSA-N
InChI=1S/C7H8N4O2.H2O/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;/h3H,1-2H3,(H,8,9);1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H8N4O2
Molecular Weight 180.164
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276

Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was primarily used as diuretic in subsequent years. It was Samuel Hirsch who discovered the bronchospasmolytic effect of theophylline in 1992, however, despite this pioneering discovery theophylline continued to be used primarily as diuretic and cardiac remedy. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes. Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Originator

Curator's Comment: Albert Kossel discovered theophylline as a component of the tea leaf

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Approved Use

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Launch Date

1982
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.3 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
95.5 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
41%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources: Page: p.500
unhealthy, 39 years (51 % < 40 years)
n = 87
Health Status: unhealthy
Condition: COPD|asthma
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Population Size: 87
Sources: Page: p.500
Disc. AE: Vomiting...
Other AEs: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3, 5.75%)
Other AEs:
Vomiting (12.64%)
Sources: Page: p.500
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Disc. AE: Gastrointestinal discomfort, Supraventricular tachycardia...
Other AEs: Tremor, Nervousness...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal discomfort (grade 3, 16.7%)
Supraventricular tachycardia (grade 3, 16.7%)
Other AEs:
Tremor (16.7%)
Nervousness (16.7%)
Dysrhythmias (grade 1, 16.7%)
Sources: Page: p.149
800 mg single, oral
Recommended
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources: Page: p.146
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M
Population Size: 6
Sources: Page: p.146
800 mg 1 times / day steady, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources: Page: p.148
unhealthy, 66 ± 9
n = 16
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 16
Sources: Page: p.148
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Other AEs: Generalized epileptic seizure, Cardiac arrhythmias...
Other AEs:
Generalized epileptic seizure (grade 4-5)
Cardiac arrhythmias (grade 4-5)
Calcium increased serum
Creatine kinase increased
Blood myoglobin increased
Leukocyte count increased
Serum phosphate decreased
Magnesium serum decreased
Acute myocardial infarction
Obstructive uropathy
Cardio-respiratory arrest (grade 5)
Hypoxic encephalopathy (grade 5)
Sources:
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (61%)
Abdominal pain (12%)
Diarrhea (14%)
Hematemesis (2%)
Hypokalemia (43%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (62%)
Supraventricular tachycardia (14%)
Premature ventricular ectopic beats (19%)
Hypotension (8%)
Nervousness (21%)
Tremor (14%)
Disorientation (11%)
Seizures (5%)
Sources:
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (30%)
Hypokalemia (44%)
Hyperglycemia (18%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (100%)
Supraventricular tachycardia (12%)
Premature ventricular ectopic beats (10%)
Atrial flutter/ fibrillation (12%)
Multifocal atrial tachycardia (2%)
Hemodynamic instability (40%)
Tremor (16%)
Seizures (14%)
Sources:
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Other AEs: Abdominal pain, Rhabdomyolysis...
Other AEs:
Abdominal pain (21%)
Rhabdomyolysis (7%)
Hypotension (21%)
Nervousness (64%)
Disorientation (7%)
Sources:
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (73%)
Hypokalemia (85%)
Hyperglycemia (98%)
Acid-base balance abnoraml (34%)
Sinus tachycardia (100%)
Supraventricular tachycardia (2%)
Premature ventricular ectopic beats (3%)
Atrial flutter/ fibrillation (1%)
Hemodynamic instability (7%)
Tremor (38%)
Seizures (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 12.64%
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources: Page: p.500
unhealthy, 39 years (51 % < 40 years)
n = 87
Health Status: unhealthy
Condition: COPD|asthma
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Population Size: 87
Sources: Page: p.500
Vomiting grade 3, 5.75%
Disc. AE
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources: Page: p.500
unhealthy, 39 years (51 % < 40 years)
n = 87
Health Status: unhealthy
Condition: COPD|asthma
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Population Size: 87
Sources: Page: p.500
Nervousness 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Tremor 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Dysrhythmias grade 1, 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Gastrointestinal discomfort grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Supraventricular tachycardia grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources: Page: p.149
unhealthy, 66 ± 9
n = 6
Health Status: unhealthy
Condition: COPD
Age Group: 66 ± 9
Sex: M+F
Population Size: 6
Sources: Page: p.149
Acute myocardial infarction
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Blood myoglobin increased
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Calcium increased serum
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Creatine kinase increased
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Leukocyte count increased
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Magnesium serum decreased
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Obstructive uropathy
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Serum phosphate decreased
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Cardiac arrhythmias grade 4-5
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Generalized epileptic seizure grade 4-5
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Cardio-respiratory arrest grade 5
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Hypoxic encephalopathy grade 5
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Sources:
Disorientation 11%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Abdominal pain 12%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Diarrhea 14%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Supraventricular tachycardia 14%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Tremor 14%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Premature ventricular ectopic beats 19%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Hematemesis 2%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Nervousness 21%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Hypokalemia 43%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Seizures 5%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Vomiting 61%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Sinus tachycardia 62%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Hypotension 8%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 102
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 102
Sources:
Premature ventricular ectopic beats 10%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Sinus tachycardia 100%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Atrial flutter/ fibrillation 12%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Supraventricular tachycardia 12%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Seizures 14%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Tremor 16%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Hyperglycemia 18%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Multifocal atrial tachycardia 2%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Vomiting 30%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Hemodynamic instability 40%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Hypokalemia 44%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
n = 92
Health Status: unhealthy
Condition: asthma|emphysema|chronic bronchitis
Population Size: 92
Sources:
Abdominal pain 21%
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Hypotension 21%
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Nervousness 64%
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Disorientation 7%
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Rhabdomyolysis 7%
10 mg/kg single, oral (min)
Overdose
unknown
n = 14
Atrial flutter/ fibrillation 1%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Sinus tachycardia 100%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Supraventricular tachycardia 2%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Premature ventricular ectopic beats 3%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Acid-base balance abnoraml 34%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Tremor 38%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Seizures 5%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Hemodynamic instability 7%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Vomiting 73%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Hypokalemia 85%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Hyperglycemia 98%
10 mg/kg single, oral (min)
Overdose
unknown
n = 157
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[The effect of GM-CSF on endothelin-1 and endothelin converting enzyme gene expression in human airway smooth muscle cells with or without theophylline incubation].
1997 Oct
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus.
1999 Jul
[A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin].
1999 Jun
Effects of Saiko-ka-ryukotsu-borei-to, a Japanese Kampo medicine, on tachycardia and central nervous system stimulation induced by theophylline in rats and mice.
1999 Mar
Gamma-aminobutyric acid and glutamic acid receptors may mediate theophylline-induced seizures in mice.
1999 Mar
Life-threatening events after theophylline overdose: a 10-year prospective analysis.
1999 May 10
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
1999 Nov
[A case of acute theophylline intoxication with repeated status convulsivus].
1999 Nov
Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature.
2000
Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions.
2000 Aug
Steroid hormone activity of flavonoids and related compounds.
2000 Jul
Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice.
2000 Oct
Oral methyl-xanthines for bronchiectasis.
2001
Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease.
2001
Treatment options for sleep apnoea.
2001
A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer.
2001
Caffeine citrate: a review of its use in apnoea of prematurity.
2001
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
2001 Apr
Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs.
2001 Apr
Caffeine metabolism before and after liver transplantation.
2001 Feb
Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2.
2001 Feb
Myocardial perfusion imaging findings and the role of adenosine in the warm-up angina phenomenon.
2001 Feb
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.
2001 Feb
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
2001 Feb
Therapeutic options for the management of patients with cardiac syndrome X.
2001 Feb
Mechanism of prolonged vasorelaxation to ATP in the rat isolated mesenteric arterial bed.
2001 Feb
K(ATP)(+) channels, nitric oxide, and adenosine are not required for local metabolic coronary vasodilation.
2001 Feb
[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
2001 Feb 1
Screening of beta-2 agonists and confirmation of fenoterol, orciprenaline, reproterol and terbutaline with gas chromatography-mass spectrometry as tetrahydroisoquinoline derivatives.
2001 Feb 10
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.
2001 Feb 15
Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers.
2001 Feb 15
The calcium-dependent [3H]acetylcholine release from synaptosomes of brown trout (Salmo trutta) optic tectum is inhibited by adenosine A1 receptors: effects of enucleation on A1 receptor density and cholinergic markers.
2001 Feb 16
[Cerebral infarction in a patient consuming MaHuang extract and guarana].
2001 Feb 3
[Theophylline in the treatment of sleep-related breathing disorders].
2001 Jan
Development of heart failure in bradycardic sick sinus syndrome.
2001 Jan
Clinical correlations in infants in the neonatal intensive care unit with varying severity of gastroesophageal reflux.
2001 Jan
Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells.
2001 Jan
A novel transverse push-pull microprobe: in vitro characterization and in vivo demonstration of the enzymatic production of adenosine in the spinal cord dorsal horn.
2001 Jan
Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999).
2001 Jan 15
Severe hyponatremia induced by theophylline and trimethoprim.
2001 Jan 22
Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism.
2001 Jan 5
Newer and alternative non-steroidal treatments for asthmatic inflammation.
2001 Jan-Feb
Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase.
2001 Jan-Feb
Drug treatment of airway inflammation in asthma.
2001 Mar
Plasma adenosine levels and P-selectin expression on platelets in preeclampsia.
2001 Mar
Continuous venovenous haemofiltration for the treatment of theophylline toxicity.
2001 Mar
Profile of moxifloxacin drug interactions.
2001 Mar 15
Inhibitory effect of theophylline on recombinant GABA(A) receptor.
2001 Mar 5
Escape deficits induced by inescapable shock and metabolic stress are reversed by adenosine receptor antagonists.
2001 May
Patents

Sample Use Guides

For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Route of Administration: Other
1 mM theophylline inhibited histamine release from human skin mast cells
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:20:57 GMT 2023
Edited
by admin
on Fri Dec 15 15:20:57 GMT 2023
Record UNII
C137DTR5RG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THEOPHYLLINE
EP   II   INCI   ORANGE BOOK   USP   VANDF  
INCI  
Official Name English
THEOPHYLLINE [USP MONOGRAPH]
Common Name English
THEOPHYLLINE [VANDF]
Common Name English
CAFFEINE IMPURITY A [EP IMPURITY]
Common Name English
THEOLAIR-SR
Brand Name English
THEOPHYLLINE [II]
Common Name English
THEOPHYLLINE [USP]
Common Name English
THEOPHYLLINE [IARC]
Common Name English
THEOPHYLLINE [EP IMPURITY]
Common Name English
THEOPHYLLINE [INCI]
Common Name English
THEOCHRON
Brand Name English
THEOPHYLLINE [ORANGE BOOK]
Common Name English
1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-1,3-DIMETHYL-, MONOHYDRATE
Systematic Name English
Theophylline monohydrate
EP   WHO-DD  
Systematic Name English
THEOPHYLLINE MONOHYDRATE [EP MONOGRAPH]
Common Name English
Theophylline monohydrate [WHO-DD]
Common Name English
THEOPHYLLINE [JAN]
Common Name English
ELIXOPHYLLIN
Brand Name English
THEOPHYLLINE COMPONENT OF DICURIN PROCAINE
Common Name English
CAFFEINE MONOHYDRATE IMPURITY A [EP IMPURITY]
Common Name English
UNIPHYL
Brand Name English
DICURIN PROCAINE COMPONENT THEOPHYLLINE
Common Name English
THEO-24
Brand Name English
NSC-757346
Code English
MERSALYL-THEOPHYLLINE COMPONENT THEOPHYLLINE
Common Name English
DIPROPHYLLINE IMPURITY B [EP IMPURITY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C221
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
NDF-RT N0000175790
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-ATC R03DA74
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
NCI_THESAURUS C319
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
DSLD 3373 (Number of products:11)
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-ATC R03DA04
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
IARC Theophylline
WHO-ATC R03DB04
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
LIVERTOX NBK548479
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
CFR 21 CFR 862.3880
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-VATC QR03DB04
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-ATC R03DA54
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-VATC QR03DA54
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-VATC QR03DA74
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
WHO-VATC QR03DA04
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C872
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID40208361
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL190
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
RS_ITEM_NUM
1653004
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
DRUG CENTRAL
2620
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
LACTMED
Theophylline
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
IUPHAR
413
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
FDA UNII
C137DTR5RG
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
SMS_ID
100000076988
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
CAS
5967-84-0
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
DRUG BANK
DB00277
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
PUBCHEM
91268
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
RXCUI
10438
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY RxNorm
NSC
757346
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
WIKIPEDIA
THEOPHYLLINE
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
CHEBI
28177
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
MESH
D013806
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
EVMPD
SUB15516MIG
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
EVMPD
SUB15520MIG
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
DAILYMED
C137DTR5RG
Created by admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY